• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Aurobindo Pharma Ltd.
    23 Apr 2025
    1093.30
    0.67%
    USFDA Grants Approval To Aurobindo Pharma's Generic Dasatinib Tablets For Cancer Treatment
    USFDA Grants Approval To Aurobindo Pharma's Generic Dasatinib Tablets For Cancer Treatment
    NDTV Profit
    The product is expected to be launched in first quarter of fiscal 2026, Aurobindo Pharma said.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1116.1
    Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?
    Business Standard | 23 Apr 2025
    logo
    Lupin Ltd.
    23 Apr 2025
    1973.60
    -0.39%
    Lupin Selects Hewlett Packard Enterprise To Modernise Private Cloud, Optimise Costs
    Lupin Selects Hewlett Packard Enterprise To Modernise Private Cloud, Optimise Costs
    NDTV Profit
    HPE's solution will enable data sovereignty, operational efficiency, faster innovation, and energy efficiency.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Sun Pharmaceutical Industries Ltd.
    23 Apr 2025
    1631.20
    -0.31%
    Indian Pharma Q4 Results Preview: Strong Sales Growth Expected To Boost Profitability In Q4
    Indian Pharma Q4 Results Preview: Strong Sales Growth Expected To Boost Profitability In Q4
    NDTV Profit
    Sun Pharma is projected to lead in PAT growth at 28% YoY, while Cipla might see a 5% YoY decline, according to Centrum Broking.
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Dr. Reddy's Laboratories Ltd.
    22 Apr 2025
    1248.10
    0.27%
    Dr Reddy's, Lupin recall products in US due to manufacturing errors: USFDA
    Business Standard
    Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1243.8
    logo
    Cipla Ltd.
    21 Apr 2025
    1517.70
    0.31%
    Cipla and CanSupport take free palliative care services to more homes in Pune
    Business Line
    With nine dedicated home care teams, the initiative will provide supportive care to more than 900 cancer patients, making it the largest home-based palliative care service in Maharashtra'
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.
    logo
    Morepen Laboratories Ltd.
    19 Apr 2025
    49.23
    0.86%
    Morepen Labs Targets Rs 5,000 Crore Revenue By FY30
    Morepen Labs Targets Rs 5,000 Crore Revenue By FY30
    NDTV Profit
    Morepen Labs aims for a 15% to 16% Ebitda margin over the next five years, and could achieve a margin of 20% in the longer run, its CMD suggested.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 57 to 49 in Jun 2025 qtr
    logo
    Glenmark Pharmaceuticals Ltd.
    18 Apr 2025
    1980.20
    1.07%
    CDSCO flags spurious batch of Telma, 131 other drugs fail quality tests
    Business Standard
    Telma 40 is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr
    logo
    FDC Ltd.
    17 Apr 2025
    461.35
    0.89%
    Govt restricts sale of anti-cold drug combination for children under 4 yrs
    Business Standard
    The FDC is also effective in treating symptoms like watery eyes, runny nose, sneezing and other discomforts
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 121 to 113 in Jun 2025 qtr
    logo
    Sanofi Consumer Healthcare India Ltd.
    17 Apr 2025
    4797.60
    1.03%
    Dividend, bonus, split: Sanofi India, 7 others to go ex-date next week
    Business Standard
    Here is the complete list of stocks to remain in focus during next week, following the announcement of corporate actions such as dividends, bonus issues, or stock-splits (subdivision)
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 136 to 114 in Jun 2025 qtr
    V
    Venus Remedies Ltd.
    17 Apr 2025
    464.90
    2.41%
    Venus Remedies shares climb 14% after US FDA grants QIDP status to VRP-034
    Business Standard
    The company's investigational product, VRP-034, has been granted QIDP designation by the US FDA for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults
    Copy LinkShare onShare on Share on Share on
    Venus Remedies Ltd. is trading below its 50 day SMA of 475.2
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • DSM Fresh Foods
    • Greenleaf Envirotech
    • NSB BPO Solutions
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)